Prostacyclin eliminates the bioincompatibility of charcoal haemoperfusion.
During charcoal haemoperfusion (CHP) in dogs, use of prostacyclin (PGI2) in addition to heparin reduced the loss of platelets (25 +/- 6 vs 83 +/- 2%), the formation of platelet aggregates as judged by screen filtration pressure (65 +/- 6 vs 249 +/- 25mm Hg) and fibrinogen consumption (20 +/- 5 vs 46 +/- 6%). Prostacyclin also delayed neutralisation of heparin during CHP. This improvement of biocompatibility may now allow a proper assessment of CHP in liver failure.
D000818:Animals; D002606:Charcoal / Q000009:adverse effects*; D004211:Disseminated Intravascular Coagulation / Q000209:etiology; D004285:Dogs; D011464:Epoprostenol / Q000494:pharmacology*; D005340:Fibrinogen; D005374:Filtration; D006464:Hemoperfusion; D006493:Heparin / Q000494:pharmacology; D010976:Platelet Count; D011453:Prostaglandins / Q000494:pharmacology*
D011453:Prostaglandins; D002606:Charcoal; D005340:Fibrinogen; D006493:Heparin; D011464:Epoprostenol